CoChat

An analysis of the attrition of drug candidates from four major pharmaceutical companies

Open access
Waring, Michael J., Arrowsmith, John, Leach, Andrew R., Leeson, Paul D., Mandrell, Sam, Owen, Robert M., Pairaudeau, Garry, Pennie, William D., Pickett, Stephen D., Wang, Jibo, Wallace, Owen, Weir, Alex · 2015 · Nature Reviews Drug Discovery

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd4609

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

Items 701–800 of 1,001

Metadata

Authors
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., & Weir, A.
Affiliations
  • AstraZeneca (United Kingdom) (GB)
  • Thomson Reuters (United Kingdom) (GB)
  • GlaxoSmithKline (United Kingdom) (GB)
  • Pfizer (United Kingdom) (GB)
  • Eli Lilly (United States) (US)
Corresponding author
Waring, Michael J.
Venue
Nature Reviews Drug Discovery
Published
2015-06-19
Volume
14
Issue
7
Pages
475-486
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W1663154925
Cited by
1,450
References
27
Citations by year
2026: 164 · 2025: 116 · 2024: 148 · 2023: 143 · 2022: 140 · 2021: 131 · 2020: 129 · 2019: 129 · 2018: 129 · 2017: 113 · 2016: 94 · 2015: 11
FWCI
12.56
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
Pfizer
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
Keywords
drug attrition, small molecule drug candidates, physicochemical properties, clinical failure, drug safety, compound optimization, oral medication, pharmaceutical industry
MeSH terms
Animals, Drug Industry, Drug Evaluation, Preclinical, Humans, Statistics as Topic, Drugs, Investigational, Drug Delivery Systems, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.